MDSpire - Takeaway
FDA & Government News

FDA Approval Advances Basal Insulin

Weekly dosing reduces injection frequency vs daily regimens, with phase 3 data supporting efficacy and class-consistent safety.

Share

  • 1

    Awiqli is the first once-weekly basal insulin approved by the FDA.

  • 2

    Administered via the FlexTouch device.

  • 3

    Reduces injections from seven to one per week.

  • 4

    Supported by ONWARDS phase 3a clinical trial results.

  • 5

    Effective in HbA1c reduction.

  • 6

    Launch expected in the US in late

  • 7

    Safety profile consistent with daily basal insulins.

Original Source(s)

FDA Approval Advances Basal Insulin

  • by Kathryn Wighton

  • March 27, 2026

Related Content

A Global Wake-Up Call on Chemical Water Quality

As new contaminants enter agrifood systems, international collaboration and analytical capacity will be key

mRNA Expands into Fertility Medicine

New study indicates that mRNA therapy can restore fertility and sperm production in previously infertile mice

  • March 27, 2026

  • 3 min
Obesity’s Cancer Role Underestimated

A proposed framework highlights potential sources of bias in current estimates